A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Blood. 2021 Feb 11;137(6):733-742. doi: 10.1182/blood.2020008021.
Blood. 2021.
PMID: 33150928
Free PMC article.